Therefore, targeting OX40/OX40L or the upstream/downstream molecules thereof in acetylation/deacetylation signaling pathways may provide more possibilities and better treatment efficacy for cancer immunotherapy, especially for chemoresistant tumors. The gene discussed is TNFRSF4; the disease is cancer.